Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing moxifloxacin for resisting pulmonary fibrosis

A technology of pulmonary fibrosis and moxifloxacin, which is applied in the field of medicine, can solve the problems of cyclophosphamide with large side effects and inaccurate curative effect, and achieve the effects of low side effects, low side effects and adverse reaction rates, and low toxicity

Inactive Publication Date: 2016-03-02
王丽
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the treatment of paraquat poisoning, glucocorticoid combined with cyclophosphamide is one of the most promising therapeutic methods, but due to the side effects of cyclophosphamide and the inaccurate curative effect, its wide application in clinical practice is limited to some extent (Green S. Systematic reviews and meta-analysis. Singapore Med J, 2005, 46:270-274)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing moxifloxacin for resisting pulmonary fibrosis
  • Pharmaceutical composition containing moxifloxacin for resisting pulmonary fibrosis
  • Pharmaceutical composition containing moxifloxacin for resisting pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Experimental study of moxifloxacin combined with curcumin against pulmonary fibrosis

[0023] 56 adult SD rats, half male and half male, weighing 200-250g. Randomly divided into: model control group, moxifloxacin treatment group, curcumin treatment group, moxifloxacin combined with curcumin treatment group; the 3 treatment groups were divided into 2 subgroups of 4d and 10d according to the course of treatment, each with 8 animals . A one-time intraperitoneal injection of 20% paraquat solution at a dose of 18 mg / kg was selected to prepare a SD rat paraquat poisoning pulmonary fibrosis model. 2h after exposure, the moxifloxacin group, curcumin group, and combination medication group were given moxifloxacin 40mg / kg, curcumin 160mg / kg, moxifloxacin 10mg / kg + curcumin 80mg / kg by gavage, repeated every 12h The administration was given once, divided into 2 courses of 4d and 10d; the model control group was given only equal volume of normal saline. On the 22nd day aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition containing moxifloxacin for resisting pulmonary fibrosis. The pharmaceutical composition comprises active components of moxifloxacin or medicinal salt thereof and curcumin. Moxifloxacin and curcumin in combination have the cooperative effect of treating paraquat poisoning-induced acute lung injury and resisting pulmonary fibrosis; the amount of moxifloxacin is only one fourth of the conventional dosage. Therefore, the composition has low cost, little side effects and low adverse reaction rate, and solves the technical problem of strong drug side effect.

Description

Technical field [0001] The present invention belongs to the technical field of medicine, and specifically relates to an anti-pulmonary fibrosis drug, in particular to an anti-pulmonary fibrosis drug composition containing a small dose of moxifloxacin. Background technique [0002] Paraquat (PQ) is an organic heterocyclic herbicide which is contact-killing, biocidal and highly toxic. It is easy to cause death of humans and animals. The lethal dose of human beings is about 30-40mg / kg, mainly due to multiple organ dysfunction (MODS) and respiration. Exhaustion. Due to the active uptake and accumulation of PQ by alveolar epithelial cells, the concentration of PQ in lung tissue after PQ poisoning can reach 10 to 90 times the plasma concentration. PQ accumulates in the type I and type II cells of the alveoli, which interferes with the redox reaction and causes Acute lung injury (ALI), even acute respiratory distress syndrome (ARDS), pulmonary fibrosis occurs later (ChenCM,LuaAC.Lungto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4709A61P11/00A61K31/12
CPCA61K31/12A61K31/4709A61K2300/00
Inventor 王丽
Owner 王丽
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com